A Study to Investigate Leramistat in Patients With IPF

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).

Key facts

Study ID

NCT05951296

Run by

Modern Biosciences Ltd

People needed

0

Starts

2023-08-30

Expected to finish

2024-03-14

Last updated by the study team

2025-04-09

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of IPF based on: a. ATS/ERS/JRS/ALAT guidelines (Raghu, 2022) as confirmed by the investigator based on chest high-resolution computed tomography (hrCT) scan taken within 3 years of Screening and, if available, surgical lung biopsy b. UIP or probable UIP hrCT pattern consistent with the clinical diagnosis of IPF, as confirmed by central review prior to baseline (if indeterminate, hrCT findings of IPF may be confirmed locally by historical biopsy).
• Has an FVC ≥45% of predicted.
• Has a DLCO corrected for hemoglobin ≥25% and ≤80% of predicted.
• Minimum distance on 6MWT of 150 meters.
• Has a FEV1/FVC ratio >0.70.
• If on anti-fibrotics, only the approved treatments of nintedanib or pirfenidone are allowed. Participants must be on a stable dose for at least 8 weeks prior to Visit 1
• Has a life expectancy of at least 12 months (in the opinion of the investigator).
• This list contains only key inclusion criteria.

You may not qualify if…

• Emphysema ≥50% on hrCT or the extent of emphysema is greater than the extent of fibrosis according to the central reviewer's assessment from the most recent hrCT or if reported by the local reviewer.
• Any current malignancy or a history of malignancy within the previous 5 years prior to screening, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
• Abnormality in heart rate, blood pressure or 12-lead ECG at screening that in the opinion of the Investigator increases the risk of participating in the study.
• Significant history of drug allergy, including to leramistat or excipients, as determined by the Investigator.
• Allergic reaction, anaphylaxis, or other reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis or leukopenia)
• History of opportunistic, chronic, or recurrent infections.
• Participants with chronic obstructive pulmonary disease (COPD) or asthma that:
• require >2 maintenance therapies
• have experienced an exacerbation requiring hospitalization or systemic corticosteroids within 12 months prior to screening.
• This list contains only key exclusion criteria.

Where it is running

• UCSF Fresno — Fresno, California, United States
• National Jewish Health Main Campus — Denver, Colorado, United States
• MedStar Georgetown University Hospital — Washington D.C., District of Columbia, United States
• Reliant Medical Research — Miami, Florida, United States
• US Associates in Research Inc — Miami, Florida, United States
• GCP Clinical Research, LLC — Tampa, Florida, United States
• GCP Clinical Research — Tampa, Florida, United States
• Southern Medical Research, LLC — Macon, Georgia, United States
• GenHarp Clinical Solutions — Chicago, Illinois, United States
• IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine — Muncie, Indiana, United States
• Benchmark Research - Covington - HyperCore - PPDS — Covington, Louisiana, United States
• University of Maryland Medical Center — Baltimore, Maryland, United States
• Howard County Center for Lung and Sleep Medicine, LLC — Columbia, Maryland, United States
• Howard County Center for Lung and Sleep Medicine, LLC — Columbia, Maryland, United States
• Hudson County Clinical Trials Research Center — Union City, New Jersey, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Southeastern Research Center — Winston-Salem, North Carolina, United States
• Baylor Scott and White Health - Advanced Lung Disease Specialists - Dallas — Dallas, Texas, United States
• Metroplex Pulmonary and Sleep Medicine Center-4833 Medical Center Dr — McKinney, Texas, United States
• Metroplex Pulmonary and Sleep Medicine Centre 4833 Medical Center Dr — McKinney, Texas, United States
• University of Utah - PPDS — Salt Lake City, Utah, United States
• Hopital Nord AP-HM — Marseille, France
• Hôpital Pasteur II — Nice, France
• Hôpital Européen Georges Pompidou — Paris, France
• Semmelweis Egyetem — Budapest, Hungary

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.